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Background: Previous studies showed that soluble LHCGR/hCG-sLHCGR concentrations in serum or plasma
combined with PAPP-A and free βhCG significantly increased the sensitivity of Down’s syndrome screen at early
pregnancy without altering the false positive rate. The goal of the present study was to further examine the role of
sLHCGR forms as combinatorial markers and to investigate whether sLHCGR could serve as an independent
biomarker for Down’s syndrome in first trimester pregnancy screens.
Methods: The PAPP-A, free βhCG, and hCG-sLHCGR concentrations together with nuchal translucency (NT) were
measured in 40 Down’s and 300 control pregnancies. The sLHCGR concentration was analysed in 40 Down’s and
206 control pregnancies.
Results: The hCG-LHCGR in combination with PAPP-A and free βhCG increased the detection rate (DR) by 35%
without altering the false positive rate (FPR). The sLHCGR: hCG-sLHCGR ratio alone detected 80% of Down’s
pregnancies in first trimester screening, with a false positive rate of 0.5%.
Conclusions: While measurement of sLHCGR forms in combination with PAPP-A and free βhCG significantly
increases the detection rate of Down’s syndrome at first trimester, the ratio of sLHCGR: hCG-sLHCGR acts as an
independent marker with a detection rate that is significantly higher than the existing biochemical markers
individually for prenatal first trimester screening of Down’s syndrome.
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Noninvasive prenatal test (NIPT), Early pregnancyBackground
Down’s syndrome (DS) occurs in about one in 800 preg-
nancies and live births from affected pregnancies lead to
serious post-natal developmental disabilities. The prevalence
of such a high frequency of trisomy 21 and other fetal
chromosomal aneuploidies led to the introduction of a
two-step clinical evaluation: a) non-invasive prenatal
screening by quantitative biochemical analysis of maternal
blood samples together with fetal ultrasonographic mea-
surements prior to b) invasive and definitive diagnosis by
genetic analysis of chorionic villous samples (CVS) and
amniotic cells. The highest sensitivity detection rate
(DR) of the current first trimester prenatal screening* Correspondence: dr_sbanerjee@hotmail.com
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be between 75% and 90% with a false positive rate (FPR)
of 3-5% [1,2]. The recent development of extensive se-
quencing of fetal DNA extracted from maternal plasma is
safer for the pregnancy and outperforms the traditional
prenatal screening methods with respect to the sensitivity
and specificity of Down’s syndrome screen [3-5].
The human chorionic gonadotropin (hCG) together
with its cognate receptor (LH/hCG-R or LHCGR) are
‘master-regulators’ of embryo implantation and pregnancy
maintenance. The placental expression of mature LHCGR
is severely down-regulated in trisomy 21 pregnancies
[6,7]. The functional state of hCG, however, may also be
regulated by the circulating soluble LHCGR (sLHCGR).
We have demonstrated that maternal serum concentra-
tions of both sLHCGR and hCG-sLHCGR at the first
trimester of Down’s pregnancy were outside the normaltral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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http://www.biomedcentral.com/1471-2393/14/197range, being either undetectable (very low) or extremely
high [8].
Our previously published data suggested that simple
measurement of hCG-sLHCGR and sLHCGR did not
have utility as independent biomarkers for Down’s syn-
drome, but that they did have utility for the increased
detection of Down’s syndrome at first trimester when
used in combination with PAPP-A, free βhCG and other
biophysical markers [8]. In this report we have taken a
different approach towards the analysis of hCG-sLHCGR
and sLHCGR measurements in order to further explore
their utility as first trimester stand-alone markers for
Down’s syndrome.
Methods
This case‐control retrospective study was on a general
population presenting as part of the universal prenatal first
trimester screening program for aneuploides (9+0-13+6
weeks of gestation) at the Department of Maternal‐Fetal
Medicine, Hospital Clinic Barcelona. This study approach
was approved by the Scientific Ethical Committee of the
Hospital Clinic Barcelona, Universitat de Barcelona. All
women participating in this study gave written informed
consent during first trimester Down's syndrome screen-
ing.The samples are derived from retrospective studies at
Barcelona Clinic. The control samples were collected on
the same day as Down’s (but were without detectable
chromosomal abnormalities) and the samples were stored
at-80°C under same conditions as the control samples.
Analysis of the serum biomarkers and nuchal trans-
lucency (NT) scan were conducted on 12,204 pregnant
women of all maternal ages to obtain 40 Down’s serum
samples.
300 control sample concentrations obtained for PAPP-A,
free βhCG and NT were converted into multiples of the
median (MoMs) for the corresponding gestational age and,
after applying correction factors for diabetes, weight, IVF,
ethnicity and smoking status, the risk at term for Down
Syndrome, Edwards Syndrome and Patau’s Syndrome was
estimated. Risk calculation was based on the Lifecycle pro-
gram version 3.2 (Perkin Elmer). For diagnosis, the CVS
(89.1%) or amniocentesis (10.9%) was programmed on the
same day if the estimated risk for aneuploidies at term was
1:250 or above. The sLHCGR and hCG-LHCGR ELISA
assays were carried out exactly as described [8] except
with the following modifications: 50 μl of 5 to 10-fold
diluted serum was incubated in antibody-coated plates
for 15 min prior to adding 100 μl of Horse Radish
Peroxidase-labelled detection antibody for another 90 min.
Following six washes, the plates were further incubated
with 100 μl of TMB for 15–30 min. Following meas-
urement of each analyte, the ratio of the multiplicity of
median (MoM) sLHCGR :MoM hCG-sLHCGR was calcu-
lated for each serum.To visualize the difference in the distribution of results
in DS cases and controls, the data were log-transformed
and plotted in a box-plot (see Figure 1a). A small quantity,
equal to 1/10 of the smallest measurable sample concen-
tration, was artificially added to the hCG-sLHCGR values
to avoid zeros in the log-transformation. The statistical
significance of the difference in the medians of the two
samples was calculated using a Wilcoxon rank-sum
method.
The median Trisomy 21 DR and 95% confidence inter-
vals at 5% and 10% FPR were determined by re-sampling
using the R pROC package. AUCDF is the estimated area
under the smoothed receiver operating characteristic
(ROC) curve which was calculated using a distribution-
free method [9]. Smoothing was accomplished by the
default method in the pROC package or by the 'density'
method of the same package as appropriate. The ROC
curves for each Down’s marker including sLHCGR/
hCG-LHCGR ratio were determined using pROC as de-
scribed [10].
Results
Consistent with our published data [8], the serum hCG-
sLHCGR together with PAPP-A detected additional DS
pregnancies which were negative by free hCGbeta plus
PAPP-A screening procedure (discussed below). There-
fore, sLHCGR/hCG-sLHCGR has an additive effect on
the current primary biochemical screening of aneuploid
pregnancies at the first trimester.
In an alternative analysis of 40 Down’s and 300 control
samples, the sensitivity of multiple biochemical markers
combined with NT at FPR of 5% and 10% were calcu-
lated. The results are shown in Table 1. It is evident
that, in a two-marker combination, PAPP-A plus hCG-
sLHCGR provided the highest DR of 81% and 84% at 5%
and 10% FPR, respectively. Moreover, addition of the
third marker (NT) in combination with PAPP-A + hCG-
sLHCGR reduced the FPR from 10% to 5% without
affecting the DR (84%). Interestingly, the addition of a
fourth marker (βhCG) which increased the DR to 90%
had also increased the FPR to 10%. Of note, the mater-
nal age and other parameters were not included in the
algorithm.
The data presented in Table 1, as well our previously
published report [8], suggested that hCG-sLHCGR and
sLHCGR had utility in combination with PAPP-A, free
βhCG and other markers, but might be limited in use
as independent markers. However, when the ratio of
sLHCGR and hCG-sLHCGR was examined, it was found
to be significantly higher in DS pregnancies compared to
controls. Such analysis revealed that the sLHCGR forms
(sLHCGR and hCG-sLHCGR ratio with a cut-off of ≥ 2.0)
could detect 80% of Down’s cases with a FPR of 0.48%
(Figure 1a).
Figure 1 The predictive value of the ratio of LHCGR forms in the detection of Down’s syndrome. a) Box-plots showing sLHCGR
MoM:hCG-sLHCGR MoM ratio of the control (N, 206) and DS (N, 40) pregnancies; b) The ROC for each Down’s marker. The ‘Ratio’ represents
Log (sLHCGR:hCG-LHCGR).
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of the impact of individual biochemical markers including
sLHCGR/hCG-sLHCGR ratio and NT on the screening of
trisomy 21 pregnancies. The highest detection rates with
an AUC of 0.9524 (0.9091-0.9958) for LHCGR/hCG-
sLHCGR were 87.5% (75% - 97.5%) and 87.5% (77.5% -
97.5%) at FPR of 5% and 10%, respectively (Figure 1b).
These results led to the conclusion that sLHCGR
forms could act as independent markers in first trimes-
ter screening for Down’s syndrome and, as such, are
more efficient than PAPP-A, free-βhCG or NT alone.
Discussion
An important objective of this study was to examine
whether serum LHCGR could increase the screening
efficiency of PAPP-A plus free–βhCG which are currently
used as first trimester biochemical markers together with
NT for prenatal risk assessment of fetal aneuploidy. In
order to compare the relative screening efficiencies in this
study, first the DR and FPR at fixed cut-off values for
PAPP-A (≤0.5 MoM), βhCG (≥1.7 MoM), hCG-sLHCGRTable 1 Detection of Trisomy 21 with fixed false positive rate
Markers AUCDF
βhCG + PAPPA 0.918
PAPPA + NT 0.922
PAPPA + hCG-sLHCGR 0.92
βhCG + hCG-sLHCGR 0.856
βhCG + NT 0.753
hCG-sLHCGR + NT 0.888
NT + PAPPA + βhCG 0.94
NT + PAPPA + hCG-sLHCGR 0.928
hCG-sLHCGR + NT + PAPPA + βhCG 0.966(≤2.0 & ≥ 20.0 MoM) were calculated. Out of all combina-
tions, the DR for Down’s syndrome with PAPP-A plus
hCG-sLHCGR was highest (57.5%) with FPR of 2.3%.
These results were comparable (DR, 58.1% and FPR, 4.5%)
to our published data on 43 Down’s samples from two
sources [8]. The additive effect of hCG-sLHCGR on
PAPP-A and βhCG measurement was 35%, compared to
21% in published data, [8]. The additive effect is defined
as T21 pregnancies identified by the PAPP-A + hCG-
sLHCGR which could not be detected by conventional
PAPP-A and βhCG measurements. Additionally, hCG-
sLHCGR, in combination with PAPP-A, βhCG and NT
(≥.2.0 MoM), detected 95% (38/40) DS pregnancies. To-
gether, the data presented here demonstrate that serum
sLHCGR/hCG-sLHCGR alone or in combination with
existing markers can increase the DR and reduce the
FPR in Down’s screening.
A limitation of this study is that the cut-off value for
sLHCGR:hCG-LHCGR ratio of ≥ 2.0 was established
on analysis of samples derived from a single center
(Figure 1). Therefore, it must be emphasized that largers
5% FPR 10%FPR
0.49(0.27 – 0.73) 0.73(0.55 – 0.92)
0.66(0.5 – 0.81) 0.78(0.64 – 0.9)
0.81(0.68 – 0.91) 0.84(0.74 – 0.95)
0.53(0.39 – 0.75) 0.65(0.5 – 0.83)
0.23(0.11 – 0.37) 0.36(0.23 – 0.51)
0.71(0.56 – 0.84) 0.77(0.63 – 0.88)
0.59(0.35 – 0.83) 0.83(0.66 – 0.97)
0.84(0.72 – 0.95) 0.87(0.76 – 0.98)
0.83(0.73 – 0.92) 0.9(0.82 – 0.97)
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high-risk groups, are required to establish the cut-off
values for serum sLHCG/hCG-sLHCGR to detect DS.
Currently, the routine non-invasive prenatal testing
(NIPT) involves the biochemical screening of maternal
serum biomarkers (PAPP-A and free - βhCG) at 9–14
wks of gestation as well the measurement of fetal NT. The
algorithms based on these results, and other parameters
including maternal age, body mass index (BMI), parity
(twin or singleton) etc., are used to assess the risk for fetal
aneuploidy. The biochemical and NT testing together
could detect 79-90% of trisomy 21 at a FPR of 5% [1,2].
The screen-positive pregnancies, following initial risk
assessment, are referred to more invasive genetic and
molecular testing by CVS/amniocentesis for definitive diag-
nosis of aneuploidy or other chromosomal abnormalities.
Current guidelines on NIPT proposed by the Inter-
national Society for Prenatal Diagnosis and others [11-13]
support the idea of cfDNA testing on ‘high-risk’ pregnan-
cies only. The high-risk was defined on the basis of mater-
nal age (≥35 yrs), screen-positives by biochemical and
ultrasound testing, history of aneuploidy and parental bal-
anced Robertsonian translocation associated with trisomy
13 and 21 [11]. In the absence of sufficient validation
of the cfDNA testing for fetal aneuploidy, it should be
considered as ‘advanced screening test’ and is not fully
diagnostic. Additionally, the current cfDNA testing for
aneuploidy is insufficient to account for half the chromo-
somal abnormalities detected by molecular analysis of
samples derived from CVS or amniocentesis [14].
While non-invasive fetal DNA sequencing provides the
highest sensitivity for T21 screening, a major disadvantage
is the cost of introducing fetal DNA sequencing as a
universal screening method for low as well as high risk
populations. As discussed recently [15,16], a cost-effective
prenatal screening strategy would initially employ the
traditional first trimester screening and subsequently
analyze only the high-risk pregnancies using the relatively
expensive DNA-sequencing method. Therefore, increased
sensitivity with simultaneous reduction in false positive
rates in conventional prenatal screening could be the most
economical avenue for successfully implementing the fetal
DNA sequencing scheme for the diagnosis of trisomic 21
pregnancies in the general population.
Compared to the fetal DNA sequencing scheme, which
is highly specific and sensitive [4,5,15,16], sLHCGR bio-
markers are more broad-ranging. The hormone hCG is
the earliest embryonic signal which directly modulates
placental growth, angiogenesis and fetal development.
Our current and previous analyses of >1000 pregnancies
suggest that hCG functions are partly regulated by circu-
lating sLHCGR. The serum sLHCGR, at intermediate
concentrations appears to be necessary for maintaining
normal pregnancy. However, soluble LHCGR at very lowand extremely high concentrations are strongly associated
with adverse pregnancy outcome. The dramatic reduction
of full-length LHCGR expression in Down’s syndrome
chorionic villi [6,7] points toward a physiological role for
sLHCGR in hCG signalling at early pregnancy. While the
precise nature of this role is not known, the impact of high
serum LHCGR in pregnancy could be two-fold: reduced
hCG bioactivity and aberrant systemic vasculo-endothelial
and immune activation.
Given the fundamental role of hormone hCG and its
receptor LHCGR throughout pregnancy, it is perhaps to
be expected that measurement of sLHCGR forms may
also detect other pregnancy pathologies, in addition to
being a useful first trimester biochemical adjunct for the
detection of DS. Indeed, sLHCGR forms have shown
preliminary success as predictive diagnostics for a wide
range of pregnancy pathologies including miscarriage,
preeclampsia and pre-term delivery. The sLHCGR system
may therefore complement, rather than directly compete
with, existing and emerging technologies by providing
early indication of those at most risk. It should be noted
however that the diagnostic capacity of serum sLHCGR
forms as biomarkers for other pregnancy pathologies, has
yet to be extensively explored and requires full clinical
validation.Conclusions
The free beta subunit of the pregnancy hormone (free-
βhCG) together with PAPP-A constitutes the fundamental
serum analytes for prenatal screening of Down’s and other
trisomic fetuses at the first trimester of pregnancy. Previ-
ous studies showed that soluble hCG receptor (sLHCGR)
in combination with PAPP-A could detect Down’s preg-
nancies which remained undetected by PAPP-A plus
free- βhCG. The present study suggests that the ratio of
the serum LHCGR forms (sLHCGR:hCG-sLHCGR) could
serve as a superior independent marker for Down’s
syndrome and significantly increase the efficiency of
the current prenatal screening program without com-
promising the false positive rate.Competing interests
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